ArticleHemaSphere2024

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.

Maeve A O'Reilly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.